GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Agentix Corp (OTCPK:AGTX) » Definitions » Capex-to-Revenue

Agentix (Agentix) Capex-to-Revenue : 0.00 (As of Dec. 2023)


View and export this data going back to 2015. Start your Free Trial

What is Agentix Capex-to-Revenue?

Capex-to-Revenue measures a company's investments in physical assets such as property, industrial buildings or equipment to its revenue.

Agentix's Capital Expenditure for the three months ended in Dec. 2023 was $0.00 Mil. Its Revenue for the three months ended in Dec. 2023 was $0.00 Mil.

GuruFocus do not calculate Capex-to-Revenue if the revenue is negative.


Agentix Capex-to-Revenue Historical Data

The historical data trend for Agentix's Capex-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Agentix Capex-to-Revenue Chart

Agentix Annual Data
Trend Aug14 Aug15 Aug16 Aug17 Aug18 Aug19 Aug20 Aug21 Mar23
Capex-to-Revenue
Get a 7-Day Free Trial Premium Member Only - - - - -

Agentix Quarterly Data
Feb19 May19 Aug19 Nov19 Feb20 May20 Aug20 Nov20 Feb21 May21 Aug21 Nov21 Feb22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Capex-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Agentix's Capex-to-Revenue

For the Biotechnology subindustry, Agentix's Capex-to-Revenue, along with its competitors' market caps and Capex-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Agentix's Capex-to-Revenue Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Agentix's Capex-to-Revenue distribution charts can be found below:

* The bar in red indicates where Agentix's Capex-to-Revenue falls into.



Agentix Capex-to-Revenue Calculation

Agentix's Capex-to-Revenue for the fiscal year that ended in Mar. 2023 is calculated as

Capex-to-Revenue=- Capital Expenditure / Revenue
=- (0) / 0
=N/A

Agentix's Capex-to-Revenue for the quarter that ended in Dec. 2023 is calculated as

Capex-to-Revenue=- Capital Expenditure / Revenue
=- (0) / 0
=N/A

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Agentix  (OTCPK:AGTX) Capex-to-Revenue Explanation

Capex-to-Revenue measures a company's investments in physical assets such as property, industrial buildings or equipment to its revenue. The ratio shows how aggressively the company reinvests its revenue back into productive assets. However, a high ratio potentially indicates that the company has invested too much in innovation and infrastructure, taking up funds that could be used to boost productivity and increase revenue. Therefore, a high Capex to Revenue Ratio could be a positive or a negative sign depending on how effectively a company converts those investments into future earnings.


Agentix Capex-to-Revenue Related Terms

Thank you for viewing the detailed overview of Agentix's Capex-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Agentix (Agentix) Business Description

Traded in Other Exchanges
N/A
Address
32932 Pacific Coast Highway, Suite 14-254, Dana Point, CA, USA, 92629
Agentix Corp is a biotechnology company. It is engaged in the development and commercialization of novel therapeutics to treat metabolic diseases, peripheral neuropathy, progressive lung disease, and ischemic reperfusion injury. Its principal business objective is to develop both science-driven synthetic and natural cannabinoid therapeutics that address unmet medical needs and continue to drive innovations in the endocannabinoid space.
Executives
Thomas E Puzzo 10 percent owner 4216 NE 70TH STREET, SEATTLE WA 98115
Michael Winterhalter director, 10 percent owner, officer: President, CEO, CFO, Treasurer 32932 PACIFIC COAST HIGHWAY, #14-254, DANA POINT CA 92629
Grays Peak Ventures Llc 10 percent owner 320 PARK AVE, NEW YORK NY 10022
Scott B Stevens director, officer: President and Director 9701 WILSHIRE BLVD., SUITE 1000, BEVERLY HILLS CA 90212
Robert K Whalen director, officer: Secretary and Treasurer 32932 PACIFIC COAST HIGHWAY, #14-254, DANA POINT CA 92629
Scott Thomas director 14 MONARCH BEACH PLAZA, SUITE 254, MONARCH BEACH CA 92629
Robert Drust director 14 MONARCH BEACH PLAZA, SUITE 254, MONARCH BEACH CA 92629
Eric Krogius director, 10 percent owner 32932 PACIFIC COAST HIGHWAY, #14-254, DANA POINT CA 92629
Bao Dong Han 10 percent owner 32932 PACIFIC COAST HIGHWAY, #14-254, DANA POINT CA 92629

Agentix (Agentix) Headlines

No Headlines